Proteomic analysis of cancer associated proteins in the solid neoplasm -The analysis for individualized therapy for lung cancer-

实体瘤中癌症相关蛋白的蛋白质组学分析-肺癌个体化治疗分析-

基本信息

批准号：
15390423
负责人：
HIRANO Takashi
金额：
$ 5.31万
依托单位：
Tokyo Medical University
依托单位国家：
日本
项目类别：
Grant-in-Aid for Scientific Research (B)
财政年份：
2003
资助国家：
日本
起止时间：
2003 至 2005
项目状态：
已结题

项目摘要

1.Gel based proteomics(1)Analysis of proteins associated with histopathological types of lung cancer : 47 proteins (15 adenocarcinoma associated proteins, 16 squamous cell carcinoma associated proteins and 16 neuroendocrine carcinoma associated proteins) were identified using 2 dimensional polyacrylamide gel electrophoresis (2DE) and mass spectrometry (MS). The validation analysis is on going. We suggest the possibility of the classification based on proteomic profiles and the selection of the therapeutic strategy.(2)Analysis of CDDP resistance associated proteins : The spots of GST-π and reticulocalbin (RCN) were identified on 2DE gel, and we proposed the possibility that the responders for platinum based chemotherapy were selected postoperatively. Furthermore, we detected 107 proteins with more than 1.5 fold overexpression and 120 proteins with less than 0.75 fold reduced expression using Ettan DIGE System.(3)We detected 40 and 33 proteins in which the expression levels were changed … More by two kinds of tyrosine kinase inhibitors. These protein molecules were identified by MS, and sequentially we are carrying out the validation analysis.2.Proteomic analysis using Liquid Chromatography-MS (LC-MS)(1)Analysis of lymph node involvement associated proteins in lung adenocarcinoma : We compared protein expression profiles between t2 no cases and t1 n(+) cases. We detected 604 candidate proteins associated with lymph node involvement. The identification and validation are on going.(2)Exploration of the biomarkers for the early detection of lung adenocarcinoma : We analyzed sera of the patients with stage IA and stage III adenocarcinomas, and thirty candidate biomarkers for early detection were detected. We validated seven candidate proteins using already established assay systems. The values of some candidate proteins were elevated in the sera of adenocarcinoma patients, but there are no statistically significant differences between the sera of adenocarcinoma patients and healthy donors. Therefore, we did not recognize the usefulness of the biomarlcers for early detection.There is a high possibility that the classification based on proteomic profile reflects biological characteristics of cancerous cells. We schedule the further investigations and evaluations for the follow-up and therapeutic strategies towards the individualized therapy of lung cancer patients. Less

1.基于凝胶的蛋白质组学（1）分析与肺癌的组织病理学类型相关的蛋白质：47种蛋白质（15种腺癌相关蛋白，16种鳞状细胞癌相关蛋白和16个神经内分泌癌蛋白相关的蛋白质）使用2二二烯酰胺凝胶电力层（MSS）和2DECENCERENCES（MS）（2DDDDER）鉴定出。验证分析正在进行中。我们建议在2DE凝胶上鉴定出基于蛋白质组学特征和理论策略的分类的可能性。（2）分析CDDP抗性相关蛋白的分析：GST-π和网状网碱（RCN）的斑点，并在2DE凝胶上鉴定出对铂基化学疗法的反应者的可能性，我们提出了对基于铂基化学疗法的响应的可能性。此外，我们检测到107种超过1.5倍过表达的蛋白质和120个蛋白质的蛋白质，使用Ettan Dige系统降低了表达。（3）我们检测到了40和33蛋白，其中表达水平被更改了……更多地通过两种酪氨酸激酶抑制剂更改了表达水平。通过MS鉴定这些蛋白质分子，然后依次进行验证分析。2。使用液相色谱MS（LC-MS）（1）分析淋巴结涉及肺腺癌中相关蛋白的分析：我们比较了T2 NO和T1 NO病例和T1 N（T1 N（+）情况之间的蛋白质蛋白质表达谱。我们检测到与淋巴结受累相关的604种候选蛋白。（2）对肺腺癌早期检测的生物标志物的探索：我们分析了IA期和III期腺癌患者的血清，以及三十个候选生物标志物的早期检测。我们使用已经建立的测定系统验证了七个候选蛋白质。在腺癌患者的血清中，某些候选蛋白的值升高，但是腺癌患者的血清和健康供体的血清之间没有统计学上的显着差异。因此，我们没有认识到生物粒子对早期检测的有用性。基于蛋白质组学谱的分类很可能反映了取消细胞的生物学特征。我们为肺癌患者的个性化治疗的随访和治疗策略进行进一步的研究和评估。较少的